![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
The net proceeds of the financing round will be used to to discover precision medicines for metabolic syndrome-related conditions and to demonstrate proof-of-concept for MultiOmic’s MOHSAIC® platform in diabetic kidney disease.
Lead Product(s): Undisclosed
Therapeutic Area: Nephrology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Hoxton Ventures
Deal Size: $8.6 million Upfront Cash: Undisclosed
Deal Type: Financing May 03, 2023